As mentioned, IL-6 plays an important role in the exhaustion and dysfunction of NK cells in patients with COVID-19 [101], so the use of an IL-6 inhibitor called tocilizumab can prevent NK cell exhaustion (Figure 2) [101,102]. Here, IL6 is linked to COVID-19.